吉西他滨联合草酸铂治疗Ⅲ～Ⅳ期非小细胞肺癌的临床观察  

Clinical Observation of Combined Chemotherapy with Gemcitabine plus Oxaliplatin in Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：徐旭[1] 王立[1] 沈波[2] 

机构地区：[1]泰州市高港人民医院,江苏泰州225321 [2]江苏省肿瘤医院,江苏南京210009

出　　处：《肿瘤基础与临床》2006年第3期213-214,共2页journal of basic and clinical oncology

摘　　要：目的观察盐酸吉两他滨联合草酸铂治疗Ⅲ～Ⅳ期非小细胞肺癌（NSCLC）的近期疗效及毒副反应。方法初治的Ⅲ～Ⅳ期NSCLC病例32例，以2l天为l周期。吉西他滨1．0g／m^2静脉滴注d1.8；草酸铂100g／m^2静脉滴注d1.8；连用2周期后评价疗效。结果全组32例均可评价疗效，总有效率37，5％（12／32）。主要毒副反应为血液学毒性，Ⅲ～Ⅳ度的白细胞下降和血小板下降分别为12．5％和15．6％。结论吉西他滨联合草酸铂治疗晚期NSCLC有较好的疗效，其毒副反应可以耐受，为晚期NSCLC提供了一种切实可行的治疗方案。Objective To evaluate the efficacy and toxicity reactions of Gemcitabine plus Oxaliplation in treatment of advanced non-small cell lung cancer （NSCLC）. Methods Selecting 32 previously not treated patients with advanced NSCLC, Gemcitabine was given on day 1,8 at a dose of 1.0g/m^2 and Oxaliplatin at a dose of 100mg/m^2 on day 1,8 .The chemotherapy was repeated every 21 days with two cycles. Results The indence rate was 37.5 % （12/32）.The main toxicity reactions were hematologic toxicity. The prevalence of grade 11 leukopenia and thrombocyte were 12.5 % and 15.6% respectively, Conclusion Gemcitabine combined with Oxaliplatin as the chemotherapy was very effective in treatment of pretreated advanced NSCLC and deserves further evaluation.

关 键 词：非小细胞肺癌 化疗 吉西他滨 草酸铂 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]